Johnson & Johnson released new data from Nipocalimab Phase II, showing that the drug improves the symptoms that patients prioritize in Sjogren's syndrome.

Zhitongcaijing · 2d ago
Johnson & Johnson released new data from Nipocalimab Phase II, showing that the drug improves the symptoms that patients prioritize in Sjogren's syndrome.